News
Latest news from CHV and our portfolio companies
Featured News
EyeCool Therapeutics, Inc. is looking forward to participating in BTIG’s 5th Annual Ophthalmology Day on Monday, December 1, 2025 from 2:30-2:55 PM ET, where leaders across the field will explore emerging innovation in ophthalmology. Our…
Insights & Impacts: The latest from CHV
The Velocity System is a next generation percutaneous AVF technology designed to reduce the need
AtaCor Medical, Inc., a privately-held medical device company focused on transforming cardiac rhythm management systems,
PanTher Therapeutics (“PanTher” or the “Company”), a clinical-stage company redefining cancer treatment with therapeutics administered
EyeCool Therapeutics, Inc., a clinical-stage medical device company pioneering a novel approach for the treatment
Instylla, Inc. announced premarket approval (PMA) from the FDA for the company’s flagship Embrace hydrogel
EyeCool Therapeutics, Inc., a clinical-stage medical device company pioneering a novel approach for the treatment
PanTher Therapeutics (“PanTher” or the “Company”), a clinical-stage company redefining cancer treatment with therapeutics administered
EyeCool Therapeutics, Inc., a clinical-stage medical device company pioneering a novel approach for the treatment
AtaCor Medical, Inc., a privately-held medical device company focused on transforming cardiac rhythm management, announced
Esperto Medical™, Inc. a healthtech startup specializing in critical care and remote patient monitoring, announces